Shuzhen Tan
Shuzhen Tan
1
School of Laboratory Medicine, Hangzhou Medical College, Hangzhou, China
2
Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Guangdong Medical University, Zhanjiang, China
1,2,†,
Zesong Li
Zesong Li
3
Guangdong Provincial Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Department of Urology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital (Shenzhen Institute of Translational Medicine), Shenzhen, China
3,†,
Kai Li
Kai Li
2
Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Guangdong Medical University, Zhanjiang, China
2,
Yingqi Li
Yingqi Li
2
Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Guangdong Medical University, Zhanjiang, China
2,
Guosheng Liang
Guosheng Liang
2
Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Guangdong Medical University, Zhanjiang, China
2,
Zhenye Tang
Zhenye Tang
2
Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Guangdong Medical University, Zhanjiang, China
2,
Jianhao Kang
Jianhao Kang
2
Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Guangdong Medical University, Zhanjiang, China
2,
Wenqing Chen
Wenqing Chen
2
Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Guangdong Medical University, Zhanjiang, China
2,
Minhua Li
Minhua Li
2
Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Guangdong Medical University, Zhanjiang, China
2,
Zhilin Zou
Zhilin Zou
2
Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Guangdong Medical University, Zhanjiang, China
2,
Guoliang Pi
Guoliang Pi
4
Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4,*,
Xiao Zhu
Xiao Zhu
1
School of Laboratory Medicine, Hangzhou Medical College, Hangzhou, China
2
Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Guangdong Medical University, Zhanjiang, China
3
Guangdong Provincial Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Department of Urology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital (Shenzhen Institute of Translational Medicine), Shenzhen, China
1,2,3,*
1
School of Laboratory Medicine, Hangzhou Medical College, Hangzhou, China
2
Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Guangdong Medical University, Zhanjiang, China
3
Guangdong Provincial Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Department of Urology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital (Shenzhen Institute of Translational Medicine), Shenzhen, China
4
Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
✉*Correspondence: Guoliang Pi, piguoliang_2004@163.com; Xiao Zhu, bioxzhu@yahoo.com
†
These authors have contributed equally to this work
This article was submitted to Molecular and Cellular Pathology, a section of the journal Frontiers in Cell and Developmental Biology
Received 2021 Dec 25; Accepted 2022 Jan 27; Collection date 2022.
Keywords: lung cancer, N6-methyladenosine, prognosis, regulators, risk scores
Copyright © 2022 Tan, Li, Li, Li, Liang, Tang, Kang, Chen, Li, Zou, Pi and Zhu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
